Gene therapy using SV40-derived vectors: What does the future hold?

Journal of Cellular Physiology

Volumn 181, Issue 3, 1999, Pages 375-384

  Strayer, David S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIMIAN VIRUS 40; TRANSGENE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; GENE THERAPY; GENETIC VECTORS; HUMANS; SAFETY; SIMIAN VIRUS 40; TRANSDUCTION, GENETIC; VIRUS CULTIVATION; VIRUS INTEGRATION; VIRUS REPLICATION;

SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0032741149     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/(sici)1097-4652(199912)181:3<375::aid-jcp1>3.0.co;2-8     Document Type: Article

References (42)

1. Anderson WF. 1994. Gene therapy and genetic diseases: revisiting the promise. Hum Gene Therapy 5:1201-1202.
2. Benedetti S, Bruzzone MG, Pollo B, DiMecco F, Pirola B, Cirenei N, Colombo MP, Finocchiaro G. 1999. Eradication of rat malignant gliomas by retroviral-mediated in vivo delivery of the interleukin 4 gene. Cancer Res 59:645-652.
3. BouHamdan M, Pomerantz RJ, Duan L-X, Strayer DS. 1999. Inhibition of HIV-1 by anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection Gene Therapy 6:660-666.
4. Breau WC, Atwood WJ, Norkin LC. 1992. Class I major histocompatibility protein share an essential component of the simian virus 40 receptor. J Virol 66:2037-2045.
5. Butel JS, Jarvis DL. 1986. The plasma-membrane-associated form of SV40 large tumor antigen: biochemical and biological properties. Biochim Biophys Acta 865:171-195.
6. Cole CN. 1996. Polyomavirinae: the viruses and their replication. In: Fields BN, Howley PM, et al, editors. Fields virology. Philadelphia: Lippincott-Raven. p 1997-2025.
7. Cole-Strauss A, Yoon K, Xiang Y, Byrne BC, Rice MC, Gryn J, Holloman WK, Kmiec EB. 1997. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science 273:1386-1389.
8. DeCaprio JA, Ludlow JW, Figge J, Shew JY, et al. 1988. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-283.
9. Fang B, Koch P, Bouvet M, Ji L, Roth JA. 1997. A packaging system for SV40 vectors without viral coding sequences. Anal Biochem 254:139-143.
10. Fried M, Prives C. 1986. The biology of simian virus 40 and polyomavirus. Cancer Cells 4:1-16.
11. Frost E, Bourgaux P. 1975. Decapsidation of polyoma virus: identification of subviral species. Virology 6:245-255.
12. Geissler E. 1990. SV40 and human brain tumors. Prog Med Virol 37:211-222.
13. Gluzman Y. 1981. SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23:175-182.
14. Gooding LR. 1977. Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells. J Immunol 118:920-927.
15. Hummeler K, Tomassini N, Sokol F. 1970. Morphological aspects of the uptake of simian virus 40 by permissive cells. J Virol 6:87-93.
16. Kondo R, Feitelson MA, Strayer DS. 1998. Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Therapy 5:575-582.
17. Lane DP, Crawford LV. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263.
18. Lednicky JA, Garcea RL, Bergsagel DJ, Butel JS. 1995. Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors. Virology 212:710-717.
19. Lee SW, Cho JA, Sung YC. 1998. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-monocyte colony-stimulating factor gene. J Virol 72:8430-8436.
20. Mackay RL, Consigli RA. 1976. Early events in polyoma virus infection: Attachment, penetration, and nuclear entry. J Virol 19:620-636.
21. Mortimer EA Jr, Lepow ML, Gold E, Robbins FC, Burton GJ, Fraumeni JF Jr. 1981. Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. N Engl J Med 305:1517-1518.
22. Myers RM Tjian R. 1980. Construction and analysis of simian virus 40 origins defective in tumor antigen binding and DNA replication. Proc Natl Acad Sci USA 77:6491-6495.
23. Oppenheim A, Sandalon Z, Peleg A, Shaul O, Nicolis S, Ottolenghi S. 1992. A cis-acting DNA signal for encapsidation of simian virus 40. J Virol 66:5320-5328.
24. Parks CL, Shenk T. 1997. Activation of the adenovirus major late promoter by transcription factors MAZ Sp1. J Virol 71:9600-9607.
25. Rosenberg BH, Deutsch JF, Ungers GE. 1981. Growth and purification of SV40 virus for biochemical studies. J Virol Methods 3:167-176.
26. Rund D, Dagan M, Dalyot-Herman N, Kimchi-Sarfaty C, Schoenlein PV, Gottesman MM, Oppenheim A. 1998. Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions. Hum Gene Therapy 9:649-657.
27. Sandalon Z, Dalyot-Herman N, Oppenheim AB, Oppenheim A. 1997. In vitro assembly of SV40 virions and pseudovirions: vector development for gene therapy. Hum Gene Therapy 8:843-849.
28. Sandalon Z, Oppenheim A. 1997. Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells. Virology 237:414-421.
29. Smith AE. 1995. Viral vectors in gene therapy. Annu Rev Microbiol 49:807-838.
30. Shah K, Nathanson N. 1976. Human exposure to SV40: review and comment. J Epidemiol 103:1-12.
31. Stang E, Kartenbeck J, Parton RG. 1997. Major histocompatibility complex class I molecules mediate association of SV40 with caveolae. Mol Biol Cell 8:47-57.
32. Strayer DS. 1996. SV40 as an effective gene transfer vector in vivo J Biol Chem 271:24741-24746.
33. Strayer DS, Milano J. 1996. SV40 mediates stable gene transfer in vivo. Gene Ther 3:581-587.
34. Strayer DS, Duan, L-X Ozaki I, Milano J, Bobraski LE, Bagasra O. 1997a. Titering Replication-Defective virus for use in gene transfer. BioTechniques 22:447-450.
35. Strayer DS, Kondo R, Milano J, Duan L-X. 1997b. Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells. Gene Therapy 4:219-225.
36. Strayer DS, Zern MA. 1999. Gene delivery to the liver using simian virus 40-derived vectors. Sem Liver Dis in press.
37. Strickler HD, Rosenberg PS, Devesa SS, Hertel J Fraumeni, JF Jr. Goedert, JJ. 1998. Contamination of poliovirus vaccines with simian virus 40 1955-1963. and subsequent cancer rates. JAMA 279: 292-295.
38. Sweet BH, Hilleman MR. 1960. The vacuolating virus S.V.40. Proc Soc Exp Biol Med 105:420-427.
39. Tamiya T, Wei MX, Chase M, Ono Y, Lee F, Breakefield XO, Chiocca EA. 1995. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral expression vectors. Gene Therapy 2:531-538.
40. Tornow J, Polvino-Bodnar M, Santangelo G, Cole CN. 1985. Two separable functional domains of simian virus 40 large T antigen: carboxyl-terminal region of simian virus 40 large T antigen is required for efficient capsid protein synthesis. J Virol 53:415-424.
41. Wang B, Godillot AP, Madaio MP, Weiner DB, Williams WV. 1998. Vaccination against pathogenic cells by DNA inoculation. Curr Top Microbiol Immunol226:21-35.
42. Zern MA, Ozaki I, Duan L, Pomerantz RP, Liu S-L, Strayer DS. 1999. A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Therapy 6:114-120.